Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics (Nasdaq: NKTR) management will present at two upcoming investor conferences: the Jefferies Healthcare Conference in New York City on June 6, 2024, at 3:30 p.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024, at 2:00 p.m. ET.
The presentations will be webcast live and accessible via the Investor Events section on the Nektar website. Recordings of the webcasts will be available until July 6, 2024, and July 10, 2024, respectively.
- Nektar's management presenting at major conferences may increase investor visibility.
- Webcast availability provides broader access to the presentations.
- Presence at renowned conferences like Jefferies and Goldman Sachs signals industry relevance.
- The press release lacks specific updates on clinical trials or financial performance.
- No immediate impact on stock value is guaranteed from presentations themselves.
- Jefferies Healthcare Conference in
New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time - Goldman Sachs 45th Annual Global Healthcare Conference in
Miami on Monday, June 10, 2024 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. The webcasts will be available for replay until July 6, 2024 and July 10, 2024, respectively.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco,
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302160077.html
SOURCE Nektar Therapeutics
FAQ
When will Nektar Therapeutics present at the Jefferies Healthcare Conference?
When will Nektar Therapeutics present at the Goldman Sachs 45th Annual Global Healthcare Conference?
How can I access the webcasts of Nektar's presentations?
How long will the webcasts of Nektar's presentations be available?
